Pancreatic Cancer News and Research

RSS
Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
New approach improves survival in patients with inoperable complex pancreatic adenocarcinoma

New approach improves survival in patients with inoperable complex pancreatic adenocarcinoma

MRI scans determine whether chemotherapy is working long before tumors shrink

MRI scans determine whether chemotherapy is working long before tumors shrink

Metformin reduces overall cancer risk in patients with Type 2 diabetes

Metformin reduces overall cancer risk in patients with Type 2 diabetes

De novo somatic gene mutations likely to cause hemimegalencephaly

De novo somatic gene mutations likely to cause hemimegalencephaly

Disorganized cancers more difficult to treat and consistently result in lower survival rates

Disorganized cancers more difficult to treat and consistently result in lower survival rates

A potential drug target for NK/T-cell lymphoma

A potential drug target for NK/T-cell lymphoma

Sun exposure, vitamin D and pancreatic cancer risk

Sun exposure, vitamin D and pancreatic cancer risk

Combination therapy may help defeat pancreatic cancer

Combination therapy may help defeat pancreatic cancer

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

FORMA, TD2 leverage synergistic capabilities to jointly develop transformative cancer therapies

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

TGen, Scottsdale Healthcare open INNO-206 Phase 2 trial for pancreatic cancer

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Prior chemotherapy extends postpalliative survival in pancreatic cancer

Azaya announces final results from ATI-1123 Phase I study on cancers

Azaya announces final results from ATI-1123 Phase I study on cancers

Study reveals mystery of how pancreatic cancer escapes immune detection

Study reveals mystery of how pancreatic cancer escapes immune detection

Patients with type 2 diabetes have 20% increased risk of blood cancers

Patients with type 2 diabetes have 20% increased risk of blood cancers

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

Antisense Pharma presents data from trabedersen Phase I/II cancer study at ASCO 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

New data from OncoMed’s OMP-59R5 Phase I study on advanced solid tumors

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

'Atzelberg Circle' researchers meet to advance hyperthermia as standard combination cancer therapy

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.